Cargando…

Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes

BACKGROUND: The present study aims to assess the cost-effectiveness of an influenza vaccination program for children in the Netherlands. This requires an evaluation of the long-term impact of such a program on the burden of influenza across all age groups, using a transmission model that accounts fo...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Pieter T., Backer, Jantien A., van Hoek, Albert Jan, Wallinga, Jacco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958762/
https://www.ncbi.nlm.nih.gov/pubmed/31931789
http://dx.doi.org/10.1186/s12916-019-1471-x
_version_ 1783487483643691008
author de Boer, Pieter T.
Backer, Jantien A.
van Hoek, Albert Jan
Wallinga, Jacco
author_facet de Boer, Pieter T.
Backer, Jantien A.
van Hoek, Albert Jan
Wallinga, Jacco
author_sort de Boer, Pieter T.
collection PubMed
description BACKGROUND: The present study aims to assess the cost-effectiveness of an influenza vaccination program for children in the Netherlands. This requires an evaluation of the long-term impact of such a program on the burden of influenza across all age groups, using a transmission model that accounts for the seasonal variability in vaccine effectiveness and the shorter duration of protection following vaccination as compared to natural infection. METHODS: We performed a cost-effectiveness analysis based on a stochastic dynamic transmission model that has been calibrated to reported GP visits with influenza-like illness in the Netherlands over 11 seasons (2003/2004 to 2014/2015). We analyzed the costs and effects of extending the current program with vaccination of children aged 2–16 years at 50% coverage over 20 consecutive seasons. We measured the effects in quality-adjusted life-years (QALYs) and we adopted a societal perspective. RESULTS: The childhood vaccination program is estimated to have an average incremental cost-effectiveness ratio (ICER) of €3944 per QALY gained and is cost-effective in the general population (across 1000 simulations; conventional Dutch threshold of €20,000 per QALY gained). The childhood vaccination program is not estimated to be cost-effective for the target-group itself with an average ICER of €57,054 per QALY gained. Uncertainty analyses reveal that these ICERs hide a wide range of outcomes. Even though introduction of a childhood vaccination program decreases the number of infections, it tends to lead to larger epidemics: in 23.3% of 1000 simulations, the childhood vaccination program results in an increase in seasons with a symptomatic attack rate larger than 5%, which is expected to cause serious strain on the health care system. In 6.4% of 1000 simulations, the childhood vaccination program leads to a net loss of QALYs. These findings are robust across different targeted age groups and vaccination coverages. CONCLUSIONS: Modeling indicates that childhood influenza vaccination is cost-effective in the Netherlands. However, childhood influenza vaccination is not cost-effective when only outcomes for the children themselves are considered. In approximately a quarter of the simulations, the introduction of a childhood vaccination program increases the frequency of seasons with a symptomatic attack rate larger than 5%. The possibility of an overall health loss cannot be excluded.
format Online
Article
Text
id pubmed-6958762
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69587622020-01-17 Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes de Boer, Pieter T. Backer, Jantien A. van Hoek, Albert Jan Wallinga, Jacco BMC Med Research Article BACKGROUND: The present study aims to assess the cost-effectiveness of an influenza vaccination program for children in the Netherlands. This requires an evaluation of the long-term impact of such a program on the burden of influenza across all age groups, using a transmission model that accounts for the seasonal variability in vaccine effectiveness and the shorter duration of protection following vaccination as compared to natural infection. METHODS: We performed a cost-effectiveness analysis based on a stochastic dynamic transmission model that has been calibrated to reported GP visits with influenza-like illness in the Netherlands over 11 seasons (2003/2004 to 2014/2015). We analyzed the costs and effects of extending the current program with vaccination of children aged 2–16 years at 50% coverage over 20 consecutive seasons. We measured the effects in quality-adjusted life-years (QALYs) and we adopted a societal perspective. RESULTS: The childhood vaccination program is estimated to have an average incremental cost-effectiveness ratio (ICER) of €3944 per QALY gained and is cost-effective in the general population (across 1000 simulations; conventional Dutch threshold of €20,000 per QALY gained). The childhood vaccination program is not estimated to be cost-effective for the target-group itself with an average ICER of €57,054 per QALY gained. Uncertainty analyses reveal that these ICERs hide a wide range of outcomes. Even though introduction of a childhood vaccination program decreases the number of infections, it tends to lead to larger epidemics: in 23.3% of 1000 simulations, the childhood vaccination program results in an increase in seasons with a symptomatic attack rate larger than 5%, which is expected to cause serious strain on the health care system. In 6.4% of 1000 simulations, the childhood vaccination program leads to a net loss of QALYs. These findings are robust across different targeted age groups and vaccination coverages. CONCLUSIONS: Modeling indicates that childhood influenza vaccination is cost-effective in the Netherlands. However, childhood influenza vaccination is not cost-effective when only outcomes for the children themselves are considered. In approximately a quarter of the simulations, the introduction of a childhood vaccination program increases the frequency of seasons with a symptomatic attack rate larger than 5%. The possibility of an overall health loss cannot be excluded. BioMed Central 2020-01-14 /pmc/articles/PMC6958762/ /pubmed/31931789 http://dx.doi.org/10.1186/s12916-019-1471-x Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
de Boer, Pieter T.
Backer, Jantien A.
van Hoek, Albert Jan
Wallinga, Jacco
Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title_full Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title_fullStr Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title_full_unstemmed Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title_short Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
title_sort vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958762/
https://www.ncbi.nlm.nih.gov/pubmed/31931789
http://dx.doi.org/10.1186/s12916-019-1471-x
work_keys_str_mv AT deboerpietert vaccinatingchildrenagainstinfluenzaoverallcosteffectivewithpotentialforundesirableoutcomes
AT backerjantiena vaccinatingchildrenagainstinfluenzaoverallcosteffectivewithpotentialforundesirableoutcomes
AT vanhoekalbertjan vaccinatingchildrenagainstinfluenzaoverallcosteffectivewithpotentialforundesirableoutcomes
AT wallingajacco vaccinatingchildrenagainstinfluenzaoverallcosteffectivewithpotentialforundesirableoutcomes